Effect of oxybutynin patch versus mirabegron on nocturia‐related quality of life in female overactive bladder patients: A multicenter randomized trial

Abstract

Objectives: To investigate the effect of oxybutynin patch versus b3-adrenoceptor agonist mirabegron on nocturia-related quality of life in female overactive bladder patients. Methods: In the present study, female overactive bladder patients were enrolled. The patients were randomly allocated into two groups: the oxybutynin patch group and the mirabegron group. Each of the drugs was given for 8 weeks. The changes in the total Nocturia Quality of Life Questionnaire score were evaluated. Parameters on a frequency volume chart were also evaluated. Results: In total, 100 patients (51 oxybutynin patch, 49 mirabegron) were treated with oxybutynin patch or mirabegron. The changes in the Nocturia Quality of Life Questionnaire score 4 weeks after administration were 3.8 AE 18.6 and 8.7 AE 13.1 with the oxybutynin patch group and the mirabegron group, respectively, which were significantly higher than those at the baseline. Furthermore, the changes in the Nocturia Quality of Life Questionnaire score 8 weeks after administration were 4.3 AE 16.5 and 7.7 AE 12.3, respectively. A statistical difference was seen only in the mirabegron group. Regarding the Nocturia Quality of Life Questionnaire subscores, oxybutynin patch and mirabegron significantly improved the Nocturia Quality of Life Questionnaire bother/concern subscore 4 and 8 weeks after administration, whereas the Nocturia Quality of Life Questionnaire sleep/energy subscore was not significantly improved in each period. Eight weeks after administration, 24-h frequency, 24-h urinary urgency and mean voided urine volume were improved in both groups statistically. Conclusions: The oxybutynin patch improves quality of life, focusing mainly on nocturia by improving the bother/concern subscores of the Nocturia Quality of Life Questionnaire in the short term.

Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats

“…OAB with urgent urinary incontinence has an important impact on the economic burden of patients and the medical care system, and on public health and clinical management ( Wang et al, 2019 ; Staskin et al, 2020 ; Dmochowski et al, 2021 ). Many oxybutynin preparations have been developed, including various oral preparations and solutions ( Ramsay et al, 2020 ; Vozmediano-Chicharro et al, 2020 ; Suzuki et al, 2021 ). The first developed immediate-release oral preparation has high side effects.…”